NCT00271817 - To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED) | Biotech Hunter

Enrollment

1,220

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Hypercholesterolemia

Interventions

DRUG

Comparator: ezetimibe/simvastatin + niacin (ER)

ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks

DRUG

Comparator: Placebo to ezetimibe/simvastatin

ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.

DRUG

Comparator: niacin (ER) tablet

niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks

DRUG

Comparator: ezetimibe (+) simvastatin

ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.

DRUG

Comparator: Placebo to Niacin (ER)

Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.

DRUG

Comparator: ezetimibe/simvastatin and niacin (ER)

ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks

DRUG

Comparator: ezetimibe and simvastatin

ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks

DRUG

Comparator: Placebo to niacin (ER)

Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks

All Listed Sponsors

lead

Organon and Co

INDUSTRY